Abstract. Epithelial-mesenchymal transition (EMT) has an established role in the acquisition of therapeutic resistance. Programmed cell death domain 2 (PDCD2) is involved in the progression of multiple types of cancer. However, its mechanism underlying chemoresistance in liver cancer has not been elucidated. In the present study, it was demonstrated that the sorafenib-resistant HepG2 cell line exhibited EMT and multidrug resistance (MDR) phenotypes, and reduced expression of PDCD2, by reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blot analysis and Cell Counting Kit-8. Annexin V/fluorescein isothiocyanate and cell migration assays further demonstrated that PDCD2 effectively promoted sorafenib-induced cell apoptosis and reduced cell metastasis. Mechanistically, PDCD2 inhibited the expression of Vimentin and increased the expression of E-cadherin in a Snail-dependent manner by RT-qPCR and western blot analysis. In conclusion, the present study elucidated for the first time, to the best of our knowledge, that PDCD2 sensitizes sorafenib-resistant HepG2 cells to sorafenib by the downregulation of EMT. PDCD2 may serve as a potential therapeutic target in the treatment of sorafenib-resistant liver cancer.
Introduction
Programmed cell death domain 2 (PDCD2), is a highly conserved zinc finger MYND domain-containing protein and is expressed in a variety of tissues (1) . The original PDCD2 clone (RP-8) was isolated from a rat gene that was associated with programmed cell death (2) . Generally, PDCD2 contributes to stem cell activity and tissue remodeling by the induction of apoptosis (3) . Accumulating data demonstrated that PDCD2 is involved in the development of cancer. For example, the expression of PDCD2 is decreased in gastric cancer tissue, and it may induce gastric cancer cell growth arrest and apoptosis in a p53-dependent manner (4, 5) . PDCD2 serves as a tumor suppresser gene involved in the pathogenesis of osteosarcoma (3) . However, its functions in carcinogenesis are debatable. For example, in human acute leukemia cells, PDCD2 was identified to be expressed at a high level, and its knockdown impaired cancer cell proliferation, suggesting that PDCD2 significantly facilitates leukemia progression (6) . A previous study demonstrated that PDCD2 is downregulated in drug-resistant breast cancer cells, indicating that PDCD2 may be involved in the process of the acquisition of multidrug resistance (MDR) (7) . However, at present, the underlying mechanism of the involvement of PDCD2 in drug resistance in liver cancer cells remains to be elucidated.
Liver cancer is the fifth most common type of cancer worldwide, and is the third most frequent cause of cancer-associated mortality to the poor prognosis and rapid progression (8) . Chemotherapy remains an optional treatment for liver cancer. However, drug resistance in patients diagnosed with liver cancer frequently leads to the failure of chemotherapeutic administration (9) . At present, the molecular mechanisms underlying drug resistance remain to be fully understood. Elucidating the molecular mechanisms of MDR is urgently required for the development of effective chemotherapeutic drugs. The activation of epithelial-mesenchymal transition (EMT) serves a principal role in the process of MDR (10) . Cancer stem cell (CSC)-like cells may facilitate tumor cell acquisition of chemotherapy and radiotherapy resistance by the activation of EMT (11) . The CSC-like cells are responsible for drug resistance and tumor metastasis, and are the principal reason for tumor treatment failure and cancer-associated mortality (12) . Clinically, sorafenib is the first-line treatment drug to prolong the overall survival rate of patients with advanced liver cancer (13) . However, drug resistance of sorafenib remains a primary challenge in improving the prognoses of patients with liver cancer (14) . Generally, sorafenib exerts an inhibitory function against EMT via the inhibition of mitogen-activated protein kinase (MAPK) signaling and expression of Snail in PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial-mesenchymal transition liver cancer (15) . However, sorafenib-resistant liver cancer cells exhibit EMT and MDR phenotypes, indicating that EMT is important in sorafenib-resistant liver cancer cells (16, 17) . Therefore, identifying the molecular mechanism underlying sorafenib resistance is indispensable for the development of effective chemotherapeutic treatments.
In the present study, it was demonstrated that PDCD2 was decreased in the sorafenib-resistant HepG2 cell line and that the overexpression of PDCD2 increased the sensitivity of chemoresistant HepG2 cells to sorafenib. Following experiments demonstrated that PDCD2 increased the expression of apoptotic proteins, suppressed resistant HepG2 cell metastasis and led to an elevated apoptotic rate when treated with sorafenib. Mechanistically, PDCD2 inhibited EMT, possibly in a Snail-dependent manner. Taken together, the present study preliminarily demonstrated that PDCD2 serves as a pivotal molecule to overcome therapy failure in the treatment of resistant liver cancer.
Materials and methods
Cell line and vectors. The HepG2 human liver cancer cell line was obtained from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The related sorafenib-resistant cell line (HepG2/SF) was generated by exposing cells to increasing concentrations (≤2 µM) of sorafenib. The MDR phenotype was evidenced by the half maximal inhibitory concentration (IC50; data not shown). These cells were maintained in RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco; Thermo Fisher Scientific, Inc.) at 37˚C in a 5% CO 2 humidified incubator. The PDCD2 expression vector was constructed in the Laboratory of Hepatobiliary-Pancreatic Surgery (Jilin University, Jilin, China). The PDCD2 lentiviral vector and Snail interfering vector (Snail-sh) were constructed by Shanghai GeneChem Co., Ltd. (Shanghai, China), and were transfected into HepG2 cells at a 10 multiplicity of infection (MOI) value. After 48 h, the cells were used in subsequent experiments.
Analysis of cell viability. Cell viability was detected using the Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc., Shanghai, China). Each experiment was repeated three times. In detail, the sorafenib-resistant cell line (HepG2/SF) was plated into 96-well plates with a total of 2x10 3 cells/well and subsequently treated with sorafenib (concentrations ranged between 0 and 15 µM) at 37˚C for 24 h following transfection with or without PDCD2. The cytotoxicity index was calculated as (1-OD450 of drug-treated cells/OD450 of untreated cells) x100 according to a previous study (18) . The IC50 values of sorafenib were calculated using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Transfection and cell migration assay. PDCD2 lentiviral vector was transfected into HepG2 cells at a 10 MOI value, according to the manufacturer's protocol (Shanghai GeneChem Co., Ltd.). After 48 h, the cells were assessed to detect cell migration using polycarbonate membranes with an 8-µm pore size (Corning, Inc., Corning, NY, USA). The cells (6x10 4 ) were seeded into the upper chamber with 200 µl serum-free medium, and the upper chambers were subsequently placed onto the lower chambers of 24-well culture dishes containing 500 µl RPMI-1640 containing 10% FBS. After 48 h, cells that had migrated to the outer side of the membranes were fixed with 4% paraformaldehyde for 30 min at room temperature and stained with 0.1% crystal violet for 20 min at room temperature. The number of migrated cells was counted under a light microscope (magnification, x100; Olympus CKX31; Olympus Corporation, Tokyo, Japan). Consistently, the snail interfering vector (Snail-sh) was additionally transfected into HepG2 cells at a 10 MOI value, and after 48 h, the cells were used in the following experiments.
Western blot analysis. The total proteins from cells were extracted and prepared using radioimmunoprecipitation assay buffer containing phenylmethanesulfonyl fluoride (Thermo Fisher Scientific, Inc.). Lysates were subsequently centrifuged at 11,000 x g for 15 min at 4˚C. The protein concentration was determined using a Bicinchoninic Acid Protein Assay kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA). A total of 15 µg proteins in the supernatant were separated on 10% SDS-PAGE and subsequently transferred to polyvinylidene difluoride membranes. TBS with Tween 20 containing 5% nonfat milk powder (w/v) was used to block the membranes for 2 h at room temperature. The membranes were incubated with primary antibodies against PDCD2 Evaluation of apoptosis. The cells were transfected with PDCD2 and were subsequently treated with sorafenib for 24 h. The apoptotic cells were assessed using an Annexin V/fluorescein isothiocyanate and propidium iodide apoptosis detection kit (Dojindo Molecular Technologies, Inc.). Flow cytometry was used to measure apoptosis using a Beckman Coulter flow cytometer (Beckman Coulter, Inc., Brea, CA, USA) and the data were analyzed with Kaluza software (version. no 2.0; Beckman Coulter, Inc.).
Statistical analysis. GraphPad Prism 7.0 (GraphPad Software, Inc.) was used to perform data analysis. All data are presented as the mean ± standard deviation of at least three independent experiments. Student's t-test was used to determine significant differences between groups. P<0.05 was considered to indicate a statistically significant difference.
Results

Sorafenib-resistant HepG2 cells exhibit EMT and MDR phenotypes, and decreased expression of PDCD2.
The sorafenib-resistant HepG2 cell line (HepG2/SF) was successfully established, determined by the IC50 for sorafenib (Fig. 1A) . The MDR1 level, which represents the MDR phenotype, was significantly increased in the sorafenib-resistant HepG2 cell line compared with that in its matched sensitive cell line (Fig. 1B and C) . Secondly, the expression of PDCD2 was analyzed, and the results demonstrated that the sorafenib-resistant HepG2 cells had a lower expression level of PDCD2. Furthermore, the expression of epithelial marker E-cadherin was decreased and that of the mesenchymal marker Vimentin was increased (Fig. 1B and C) . The reduced expression of PDCD2 and the elevated EMT and MDR in the sorafenib-resistant HepG2 cell line preliminarily indicated that PDCD2 may be involved in the formation of MDR by regulating EMT.
PDCD2 reverses the drug resistance of sorafenib-resistant HepG2 cells.
To further examine the function of PDCD2 in the process of MDR, the IC50 was detected following transfection of the sorafenib-resistant HepG2 cells with PDCD2. The results showed that the overexpression of PDCD2 significantly increased the sorafenib-induced cytotoxicity ( Fig. 2A) . Furthermore, the expression of MDR1 was decreased following transfection with PDCD2 ( Fig. 2B and C) . The results preliminarily demonstrated that PDCD2 may reverse the MDR of sorafenib-resistant liver cancer cells.
PDCD2 facilitates cell apoptosis and suppresses cell migration in sorafenib-resistant HepG2 cells.
To further detect the function of PDCD2 involved in MDR, the apoptotic rates of sorafenib-resistant HepG2 cells transfected with PDCD2 were measured following treatment with sorafenib. As expected, the overexpression of PDCD2 enhanced sorafenib-induced apoptosis in the drug-resistant cells as revealed by flow cytometry (Fig. 3A) . Furthermore, PDCD2 reduced the migration ability of sorafenib-resistant HepG2 cells (Fig. 3B) . Consistent with the proposed function of PDCD2, the results of the western blotting demonstrated that PDCD2 upregulated the apoptotic-associated proteins and downregulated migration-associated proteins (Fig. 3C ).
PDCD2 reduces EM T and MDR phenot ypes in a Snail-dependent manner in sorafenib-resistant HepG2 cells.
Given the fact that PDCD2 sensitizes sorafenib-resistant HepG2 cells to sorafenib, and the higher EMT phenotype is responsible for MDR, it was hypothesized that PDCD2 may affect EMT and be involved in the process of reversing MDR. The results of the western blotting demonstrated that the expression of E-cadherin was increased whereas the expression of Vimentin was decreased following transfection of the sorafenib-resistant HepG2 cells with PDCD2. Snail, a zinc-finger transcriptional repressor, is critical in EMT-mediated tumor metastasis. Its expression was additionally downregulated in the sorafenib-resistant HepG2 cells transfected with PDCD2 ( Fig. 4A and B) . A Snail interfering vector (Snail-sh) was transfected into HepG2/SF cells, and the results demonstrated a significant downregulation of Snail expression as presented in Fig. 4C and D. Cotransfection of the HepG2/SF cells with PDCD2 and Snail-sh plasmids partially blunted the MDR and EMT phenotypes, indicating that PDCD2 likely reverses MDR and EMT in a Snail-dependent manner (Fig. 4E and F) . From these results, it was ascertained that PDCD2 controls EMT via the downregulation of Snail.
Discussion
Sorafenib, with anti-angiogenic and antiproliferative effects, is a multi-kinase inhibitor that suppresses the MAPK/extracellular signal-regulated kinase, vascular endothelial growth factor receptor and platelet-derived growth factor receptor signaling pathways (15) . Generally, treatment with sorafenib leads to tumor angiogenesis suppression, cell cycle arrest and elevated apoptosis (19, 20) . However, resistance to sorafenib is a principal cause of antineoplastic treatment failure, particularly in certain patients with advanced liver cancer under long-term treatment, which causes oncogenic relapse or distant metastasis (21) . Accumulating evidence has demonstrated that EMT is the principal cause of sorafenib resistance in liver cancer cells (10, 22) . In the present study, a sorafenib-resistant HepG2 cell line was established from long-term exposure to high-dose sorafenib. Therefore, the sorafenib-resistant HepG2 cells exhibited MDR, EMT phenotypes and decreased expression of PDCD2, preliminarily indicating that PDCD2 may be involved in the process of drug resistance by modulating EMT. To further investigate the function of PDCD2 in sorafenib-resistant HepG2 cell lines in the present study, the IC50 value for sorafenib and the expression levels of MDR1 following transfection with PDCD2 were detected. The results suggested that the overexpression of PDCD2 enhanced the inhibitory effect of sorafenib, as determined by the decreased IC50 value and decreased expression of MDR1. Notably, the overexpression of PDCD2 significantly increased sorafenib-induced cytotoxicity and apoptosis, and decreased the migration rate, demonstrating that PDCD2 may reverse the MDR and EMT phenotypes in sorafenib-resistant HepG2 cells. Generally, EMT is a normal developmental program that promotes cancer cells to trigger abnormal cell migration, invasion and drug resistance (12, 23) . Therefore, EMT, as a critical regulator, is closely associated with the CSC phenotype and is a prerequisite for metastasis. The induction of EMT in epithelial cells leads to CSC characteristics, including increased stem-cell marker expression, enhanced ability to metastasize and drug resistance (24) . A number of previous studies have identified the association between EMT and drug resistance (10) (11) (12) 25) . In the present study, the increased expression of mesenchymal markers, including vimentin, and the inhibition of epithelial markers, including E-cadherin, were observed in the sorafenib-resistant liver cancer cell lines. Mechanistically, octamer binding transcription factor 4 and Nanog are essential for the maintenance of the stem cell phenotype that hijacks liver cancer cells with CSC and EMT phenotypes via activation of the signal transducer and activator of transcription 3/Snail pathway (26) . Oncogenes, including epidermal growth factor receptor, Akt and nuclear factor-κB additionally contribute to EMT (27) . However, the molecular mechanisms of how PDCD2 influences sorafenib resistance by regulating EMT in cancer cells require further elucidation.
Numerous mechanisms involved in MDR are important in the drug resistance of liver cancer, including the drug efflux pump (e.g. MDR1), EMT and DNA damage repair (28) (29) (30) . EMT is more associated with the acquisition of the MDR phenotypes in liver cancer. For example, liver cancer cells with MDR have been shown to exhibit enhanced metastatic activity, and upregulated expression of N-cadherin and Vimentin in a calcium-dependent manner (31) . In addition, a previous study demonstrated that liver cancer cells underwent EMT and exhibited increased invasiveness and MDR phenotypes when exposed to hypoxia (32) . A number of transcriptional repressors, including the Snail/Slug family, function as a molecular switch of EMT (33) . The present study examined the crosstalk between EMT and MDR involved in the acquired drug resistance to sorafenib in liver cancer, and demonstrated that the expression of Snail was decreased when the cells overexpressed PDCD2. The Snail transcription factor is pivotal in the expression of mesenchymal markers, including Vimentin, MMP2 and MMP9 in liver cancer cells (34) . Mechanistically, Snail is involved in EMT via the downregulation of cell metastasis by binding several E-boxes located in the E-cadherin promoter region (35) . The overexpression of Snail facilitates the acquisition of P-glycoprotein-mediated MDR (36) . Co-transfection of PDCD2 and Snail-sh plasmids into HepG2/SF cells partially blunted the MDR and EMT phenotypes, indicating that PDCD2 likely reversed MDR and EMT in a Snail-dependent manner. Therefore, the results indicated that PDCD2 modulates EMT by the suppression of Snail in drug-resistant liver cancer cells.
In conclusion, the present study demonstrated that sorafenib-resistant HepG2 cells exhibit EMT, MDR phenotypes and downregulated expression of PDCD2. The overexpression of PDCD2 suppressed sorafenib-resistant HepG2 cells from undergoing EMT and metastasis, and promoted cell apoptosis. Mechanistically, PDCD2 modulated EMT by the suppression of Snail in drug-resistant HepG2 cells. The results additionally identified that PDCD2, as a pivotal regulator of EMT, may serve as a potential therapeutic target in the treatment of sorafenib-resistant liver cancer.
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